我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
100.0%
暂无批准数据
- A 65-year-old colorectal cancer patient from Cardiff has become the first person in Wales to receive a personalized mRNA cancer vaccine designed to prevent disease recurrence. - The innovative trial, led by Velindre Cancer Centre in partnership with BioNTech, utilizes similar technology to COVID-19 vaccines to create patient-specific treatments targeting individual cancer profiles. - The study aims to enroll approximately 110 Welsh patients across multiple UK centers, representing a significant step forward in personalized cancer immunotherapy development.
